PMID- 24995469
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20211203
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 37
IP  - 5
DP  - 2015 May
TI  - Radioresistance in head and neck squamous cell carcinoma: Biological bases and 
      therapeutic implications.
PG  - 763-70
LID - 10.1002/hed.23837 [doi]
AB  - Head and neck squamous cell carcinoma (HNSCC) is strongly associated with alcohol 
      and tobacco consumption. Lately, the incidence of human papillomavirus 
      (HPV)-related tumors has shown a significant increase, and HPV-related tumors 
      show distinctive features if compared with the HPV-negative counterpart. Locally 
      advanced HNSCC can be treated with concomitant chemoradiotherapy, but early 
      recurrences sometimes occur. Relapses are often related to an intrinsic 
      radioresistance of the tumors. Alterations in intracellular pathways, primarily 
      involved in cell proliferation, apoptosis, and DNA repair, can lead to 
      radioresistance. Preclinical and clinical evidence highlighted that 3 main 
      pathways, including the epidermal growth factor receptor (EGFR), the 
      phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), 
      and the p53 signaling cascades, play a crucial role in radioresistance 
      development. A future approach may consist in the association of radiotherapy 
      (RT) and selective inhibition of the key pathways involved in radioresistance. 
      Phase I, II, and III clinical trials are currently testing these novel treatment 
      strategies.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Perri, Francesco
AU  - Perri F
AD  - Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, Naples, 
      Italy.
FAU - Pacelli, Roberto
AU  - Pacelli R
FAU - Della Vittoria Scarpati, Giuseppina
AU  - Della Vittoria Scarpati G
FAU - Cella, Laura
AU  - Cella L
FAU - Giuliano, Mario
AU  - Giuliano M
FAU - Caponigro, Francesco
AU  - Caponigro F
FAU - Pepe, Stefano
AU  - Pepe S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150127
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Carcinoma, Squamous Cell/drug therapy/pathology/*radiotherapy
MH  - Chemoradiotherapy/*methods
MH  - ErbB Receptors/drug effects/radiation effects
MH  - Female
MH  - Head and Neck Neoplasms/drug therapy/pathology/*radiotherapy
MH  - Humans
MH  - Male
MH  - Molecular Targeted Therapy/*methods
MH  - Prognosis
MH  - Radiation Tolerance/physiology/*radiation effects
MH  - Radiotherapy Dosage
MH  - Risk Assessment
MH  - Signal Transduction
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - TOR Serine-Threonine Kinases/drug effects/radiation effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Akt
OT  - P53
OT  - chemoradiotherapy
OT  - epidermal growth factor receptor (EGFR)
OT  - head and neck squamous cell carcinoma
OT  - intracellular pathway
OT  - radioresistance
EDAT- 2014/07/06 06:00
MHDA- 2016/01/15 06:00
CRDT- 2014/07/05 06:00
PHST- 2014/06/30 00:00 [accepted]
PHST- 2014/07/05 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
AID - 10.1002/hed.23837 [doi]
PST - ppublish
SO  - Head Neck. 2015 May;37(5):763-70. doi: 10.1002/hed.23837. Epub 2015 Jan 27.